Shuttle Pharmaceuticals, Inc. — Department of Health and Human Services SBIR Phase I: <p>The objective of this fast-track SBIR Application is to advance commercialization effor
Shuttle Pharmaceuticals, Inc. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $191,971
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- NAICS
- —
- Place of performance
- MD
- Period
- —
Description
<p>The objective of this fast-track SBIR Application is to advance commercialization efforts for IPdR (5-iodo-2pyrimidinone-2'-deoxyribose), a prod rug of the radiosensitizer IUdR (5-iodo-2'-deoxyuridine). In the Phase I SBIR, we will determine the scientific merit, feasibility and potential for commercialization of oral lPdR as a radiation sensitizer for use in cancer treatment. Administrative tasks will be completed to enable an IND for Shuttle Pharmaceuticals, LLC; formulation of GMP manufactured IPdR into 300 mg capsules; submission of a letter of intent (LOI) to CTEP; protocol preparation and IRB approval for the proposed Phase I clinical trial and establishment of companion diagnostics for analyzing clinical specimens from Phase I patients. The tasksdetailed for the Phase I effort are intended to facilitate an IND for IPdR for Shuttle Pharmaceuticals. PUBLIC HEALTH RELEVANCE</p>